Back to News
Market Impact: 0.15
Galmed Pharma Rebrands To EoCene, Debuts EOCN Ticker As GI Expansion Accelerates; Stock Up
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Clinical-stage biopharmaceutical company Galmed Pharmaceuticals announced a corporate rebrand to Eocene Ltd. and will change its Nasdaq trading symbol from GLMD to EOCN. The announcement provides no financial results, clinical-data update, or change in operating guidance.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.05
Ticker Sentiment
GLMD0.20
More News
- How Pepsi fell behind in the cola wars—and then lost KFC
- Xencor reports phase 1 data for cancer drug XmAb819
- ‘We like to be first to be second’: How True Religion’s CEO is rebuilding the denim brand for Gen Z and millennials
- Biotech stocks are surging. How investors can play the new drug innovation boom
- UK immigration crackdown threatens £15 billion care sector
- IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- How to Track Guidance Changes Across a Coverage List With AI
- Stop Treating AI Like a Chatbot: What Are Agents, SubAgents, MCP, and Skills, and How Do They Actually Work?